Updates are available Correction dated 2025-11-25

Article History

Received: 27 October 2023

Accepted: 16 February 2024

First Online: 5 April 2024

Change Date: 25 November 2025

Change Type: Update

Change Details: The original online version of this article was revised: Two authors - María Victoria García-Ortiz and Teresa Morales-Ruiz and their corresponding affiliations are included. Authors’ contributions statement is also updated.

Change Date: 25 November 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s12094-025-04113-7

Declarations

:

: Rodríguez-Lescure A has received consultant or advisory role from Roche, Lilly, Pfizer, Novartis, Daiichi-Sankyo and Astra-Zeneca; Speaker’s bureau fees from Daiichi-Sankyo, Merck and Astra-Zeneca. Gallego J has received consultant or advisory role from Amgen, Astellas, Bayer, BMS, Eisai, Ipsen, Lilly, Merck, MSD, Pierre-Fabre, Roche, Servier and Veracyte; Speaker’s bureau fees from Amgen, Bayer, BMS, Ipsen, Lilly, Merck, MSD, Novartis and Servier; Educational grants from Amgen, Ipsen, Merck, Novartis, Pierre-Fabre and Roche. Garcia-Alfonso P has received consultant or advisory role fees and Speaker’s bureau fees from Amgen, Merck Serono, MSD, Lilly, Roche, Sanofi, Servier and Pierre Fabre. Massuti B has received consultant or advisory role from Roche, Boehringer Ingelheim, Astra Zeneca, Merck Serono and Janssen; Speaker’s bureau fees from Roche, Astra Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Sanofi/Regeneron, Janssen Oncology and Pfizer; Travel accommodations expenses from Roche, MSD and Astra Zeneca. Ponce J has received consultant or advisory role from Astra Zeneca, Daiichi Sankyo, Novartis, Pierre Fabre, Roche and Seattle Genetics; Speaker’s bureau fees from Astra Zeneca, Daiichi Sankyo, Lilly, Novartis, Pfizer and Seattle Genetics. Santaballa A has received consulting or advisory role fees from GSK, Clovis, MSD, Astra Zeneca, Pfizer, Novartis and Lilly; Speaker’s bureau fees from GSK, Clovis, MSD, Astra Zeneca, Pfizer, Novartis, Lilly and Pierre Fabre; Travel accommodations expenses from Pfizer and MSD. Valladares M has received consulting or advisory role fees from Amgen, Servier and Bayer; Speaker’s bureau fees from Merk, Amgen, Servier, Bayer, Roche and Celgene; Research funding from Amgen and Roche; Travel accommodations expenses from Roche, Merk, Amgen and Servier. Alonso V has received consulting or advisory role fees from Sanofi, Amgen, Merk, Servier and Novartis; Travel accommodations expenses from Roche and Merk. Aparicio J has received consultant or advisory role fees from Amgen, Bayer, Merck, Merck Sharp & Dohme, Pierre Fabre and Servier. The rest of authors have declared no conflicts of interest.